| Drug Name |
Adalimumab |
| Drug ID |
BADD_D00041 |
| Description |
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor [A39984], [A39999]. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA [A39983]. This drug is frequently known as _Humira_. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses [A39983]. A new biosimilar to adalimumab, named _adalimumab-adaz_, was approved by the FDA on October 31, 2018. This biosimilar is known as _Hyrimoz_, and is a trademark of Novartis AG [L4799]. |
| Indications and Usage |
The following are conditions for which adalimumab has been indicated [F2118], [FDA label], [L4805], [A40001], [A40002], [L4806].
Rheumatoid Arthritis (Moderate to Severe)
Juvenile Idiopathic Arthritis (Moderately to Severely Active)
Psoriatic Arthritis (Active)
Ankylosing Spondylitis (Active)
Crohn’s Disease (Moderately to Severely Active)
Ulcerative Colitis (Moderately to Severely Active)
Plaque Psoriasis (Moderate to Severe Chronic)
Non-infectious Intermediate, Posterior and Panuveitis
Hidradenitis Suppurativa (Moderate to Severe)
Pyoderma Gangrenosum (off-label)
|
| Marketing Status |
approved; experimental |
| ATC Code |
L04AB04 |
| DrugBank ID |
DB00051
|
| KEGG ID |
D02597
|
| MeSH ID |
D000068879
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0K5KS
|
| NDC Product Code |
43835-0033; 71124-0027; 0074-0124; 49502-380; 0074-2540; 43835-0036; 50090-4487; 65219-554; 0074-0817; 0074-1115; 43835-0035; 0074-0243; 49502-382; 0074-2330; 49502-418; 71124-0023; 0074-0554; 0074-0616; 65219-556; 72606-030; 0074-1117; 0074-1867; 0074-1539; 0074-3799; 0074-4339; 0074-0067; 49502-381; 49502-417; 58394-051; 69438-0009; 49502-416 |
| UNII |
FYS6T7F842
|
| Synonyms |
Adalimumab | Humira | Adalimumab-adbm | Amjevita | Adalimumab-atto | Cyltezo | D2E7 Antibody | Antibody, D2E7 |
